Abstract
The American Academy of Allergy, Asthma & Immunology (AAAAI) and the American College of Allergy, Asthma & Immunology (ACAAI) have jointly accepted responsibility for establishing the "Practice parameter for the diagnosis and management of primary immunodeficiency." This is a complete and comprehensive document at the current time. The medical environment is a changing environment, and not all recommendations will be appropriate for all patients. Because this document incorporated the efforts of many participants, no single individual, including those who served on the Joint Task Force, is authorized to provide an official AAAAI or ACAAI interpretation of these practice parameters. Any request for information about or an interpretation of these practice parameters by the AAAAI or ACAAI should be directed to the Executive Offices of the AAAAI, the ACAAI, and the Joint Council of Allergy, Asthma & Immunology. These parameters are not designed for use by pharmaceutical companies in drug promotion.
Original language | English (US) |
---|---|
Pages (from-to) | 1186-1205.e78 |
Journal | Journal of Allergy and Clinical Immunology |
Volume | 136 |
Issue number | 5 |
DOIs | |
State | Published - Dec 30 2014 |
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
Fingerprint
Dive into the research topics of 'Practice parameter for the diagnosis and management of primary immunodeficiency'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Journal of Allergy and Clinical Immunology, Vol. 136, No. 5, 30.12.2014, p. 1186-1205.e78.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Practice parameter for the diagnosis and management of primary immunodeficiency
AU - Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma & Immunology; the American College of Allergy, Asthma & Immunology; and the Joint Council of Allergy, Asthma & Immunology
AU - Bonilla, Francisco A.
AU - Khan, David A.
AU - Ballas, Zuhair K.
AU - Chinen, Javier
AU - Frank, Michael M.
AU - Hsu, Joyce T.
AU - Keller, Michael
AU - Kobrynski, Lisa J.
AU - Komarow, Hirsh D.
AU - Mazer, Bruce
AU - Nelson, Robert P.
AU - Orange, Jordan S.
AU - Routes, John M.
AU - Shearer, William T.
AU - Sorensen, Ricardo U.
AU - Verbsky, James W.
AU - Bernstein, David I.
AU - Blessing-Moore, Joann
AU - Lang, David
AU - Nicklas, Richard A.
AU - Oppenheimer, John
AU - Portnoy, Jay M.
AU - Randolph, Christopher R.
AU - Schuller, Diane
AU - Spector, Sheldon L.
AU - Tilles, Stephen
AU - Wallace, Dana
N1 - Funding Information: Disclosure of potential conflict of interest: F. A. Bonilla has consultant arrangements with ADMA Biologics, Baxter, Cowen Group, CSL Behring, the Gerson-Lehrman Group, Grand Rounds Health, and the Immune Deficiency Foundation; has received research support from CSL Behring; has received payment for lectures from Albany Medical College; has received royalties from UpToDate in Medicine; and has received travel support from CSL Behring. D. A. Khan has received payment for lectures from Genentech, Merck, Baxter, and Viropharma; has received research support from the Vanberg Family Foundation and the National Institutes of Health (NIH)/National Institute of Mental Health; is the Allied Health Chair for the American College of Allergy, Asthma & Immunology; and is a member of the Joint Task Force to Practice Parameters for the Joint Council on Allergy, Asthma & Immunology. Z. K. Ballas has consulting arrangements with the Immune Deficiency Foundation; has received research support from the NIH Cancer Center; and has received royalties from UpToDate. M. M. Frank is on the DCMB for Biocryst and has received travel support from CSL Behring. M. Keller has received research support from the Jeffrey Modell Foundation. L. J. Kobrynski has consultant arrangements with CSL Behring; has received research support from the Centers for Disease Control and Prevention Foundation through the NIH; has received payment for lectures from Baxter Healthcare; and has received travel support and speakers' fees from the Immune Deficiency Foundation. J. S. Orange has consultant arrangements with Baxter Healthcare, CSL Behring, ASD Healthcare, ADMA Biologics, and Walgreens; has received research support from CSL Behring; has received payment for lectures from Baxter Healthcare; has received royalties from UpToDate, UniMed, and Springer; and is on the Medical Advisory Council of the Immune Deficiency Foundation. W. T. Shearer is employed by Baylor College of Medicine. J. W. Verbsky has received royalties from UpToDate. D. I. Bernstein has received research support from TEVA, Genentech, Pfizer, Merck, Meda, GlaxoSmithKline, Array, Cephalon, and MedImmune and has provided legal consultation or expert witness testimony in cases related to anaphylaxis, contact dermatitis, and occupational asthma. J. Blessing-Moore has received payment for lectures from Meda, Alcon, TEVA, Sunovion, Genentech/Novartis, Merck, and AstraZeneca; has received research support from Meda; and serves on committees for the American College of Chest Physicians, the American College of Allergy, Asthma & Immunology, the American Academy of Allergy, Asthma & Immunology, and the American Thoracic Society. D. Lang has consultant arrangements with GlaxoSmithKline, Merck, and Aerocrine; has received payment for lectures from Genentech/Novartis, GlaxoSmithKline, and Merck; and has received research support from Genentech/Novartis and Merck. R. A. Nicklas is a committee chair for the American College of Allergy, Asthma & Immunology. J. Oppenheimer has consultant arrangements with AstraZeneca, GlaxoSmithKline, Sunovion, Mylan, and Sanofi; has received research support from AstraZeneca, GlaxoSmithKline, Merck, Novartis, Boehringer Ingelheim, and MedImmune; has provided legal consultation or expert witness testimony in cases related to malpractice; is chairman of the American Board of Allergy and Immunology; and is Associate Editor of the Annals of Allergy. J. M. Portnoy has received payment for lectures from Thermo Fisher and Mylan and has consultant arrangements with Thermo Fisher and Sanofi. C. R. Randolph has received payment for lectures from GlaxoSmithKline, TEVA, ViroPharma, Merck, and Dey; has received research support from GlaxoSmithKline, Merck, Amgen, and Genentech/Novartis; and has consultant arrangements with AstraZeneca and Meda. D. Schuller has received travel support from the Joint Council of Allergy, Asthma & Immunology for Joint Task Force meetings. S. L. Spector has stock in GlaxoSmithKline and Merck; has consultant arrangements with Hycor; has received research support from AstraZeneca, GlaxoSmithKline, Amgen, Genentech, Novartis, Teva, Mylan, Sanofi, and Boehringer Ingelheim; and is a speaker/moderator for the American College of Allergy, Asthma & Immunology. S. Tilles has consultant arrangements with SRXA, Sunovion, and Hycor; has received research support from Astellas, Amphastar, Medimmune, Cephalon, Genentech, Merck, TEVA, Sunovion, Boehringer Ingelheim, Nutricia, Array, Rigel, and AstraZeneca; is Associate Editor of AllergyWatch and the Annals of Allergy; is Assistant Editor of the Joint Task Force for Practice Parameters; and is on the Executive Committee for the Seattle Food Allergy Consortium. D. Wallace has received payment for lectures from TEVA, Mylan Labs, and the American College of Allergy, Asthma & Immunology; is an advisor for Sanofi and Sunovion; is on the Executive Committee of the American College of Allergy, Asthma & Immunology; and is on the Board of Directors for the World Allergy Organization. The rest of the authors declare that they have no relevant conflicts of interest. Funding Information: This parameter was developed by a working group made up of clinical immunologists specializing in immunodeficiency. A workgroup chaired by Dr Francisco A. Bonilla prepared the initial draft, which was subsequently reviewed by the Joint Task Force. The working draft of “Diagnosis and management of primary immunodeficiency” was reviewed by several experts in allergy and immunology. These experts included reviewers appointed by the ACAAI and AAAAI. The revised final document presented here was approved by the sponsoring organizations and represents an evidence-based and broadly accepted consensus parameter. The project was exclusively funded by the 3 allergy and immunology societies noted above. Funding Information: H.D.K. is supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Md.
PY - 2014/12/30
Y1 - 2014/12/30
N2 - The American Academy of Allergy, Asthma & Immunology (AAAAI) and the American College of Allergy, Asthma & Immunology (ACAAI) have jointly accepted responsibility for establishing the "Practice parameter for the diagnosis and management of primary immunodeficiency." This is a complete and comprehensive document at the current time. The medical environment is a changing environment, and not all recommendations will be appropriate for all patients. Because this document incorporated the efforts of many participants, no single individual, including those who served on the Joint Task Force, is authorized to provide an official AAAAI or ACAAI interpretation of these practice parameters. Any request for information about or an interpretation of these practice parameters by the AAAAI or ACAAI should be directed to the Executive Offices of the AAAAI, the ACAAI, and the Joint Council of Allergy, Asthma & Immunology. These parameters are not designed for use by pharmaceutical companies in drug promotion.
AB - The American Academy of Allergy, Asthma & Immunology (AAAAI) and the American College of Allergy, Asthma & Immunology (ACAAI) have jointly accepted responsibility for establishing the "Practice parameter for the diagnosis and management of primary immunodeficiency." This is a complete and comprehensive document at the current time. The medical environment is a changing environment, and not all recommendations will be appropriate for all patients. Because this document incorporated the efforts of many participants, no single individual, including those who served on the Joint Task Force, is authorized to provide an official AAAAI or ACAAI interpretation of these practice parameters. Any request for information about or an interpretation of these practice parameters by the AAAAI or ACAAI should be directed to the Executive Offices of the AAAAI, the ACAAI, and the Joint Council of Allergy, Asthma & Immunology. These parameters are not designed for use by pharmaceutical companies in drug promotion.
UR - http://www.scopus.com/inward/record.url?scp=84960964432&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84960964432&partnerID=8YFLogxK
U2 - 10.1016/j.jaci.2015.04.049
DO - 10.1016/j.jaci.2015.04.049
M3 - Article
C2 - 26371839
AN - SCOPUS:84960964432
SN - 0091-6749
VL - 136
SP - 1186-1205.e78
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
IS - 5
ER -